10-Q: Seer, Inc. Q1 2026 Financials Show Revenue Decline

Seer, Inc. reported a 34% decrease in total revenue for the first quarter of 2026 compared to the prior year, driven by lower product and service sales.

Summary

• Seer, Inc. reported total revenue of $2.8 million for the three months ended March 31, 2026, a decrease of 34% from $4.2 million in the same period of 2025.
• Product revenue decreased by 27% to $2.1 million, and service revenue decreased by 55% to $0.5 million.
• Cost of revenue decreased by 16% to $1.8 million, resulting in a gross profit of $0.98 million, down 52% from $2.1 million in the prior year.
• Operating expenses decreased by 20% to $18.2 million, primarily due to reductions in research and development and selling, general, and administrative expenses.
• The company reported a net loss of $16.8 million for the quarter, an improvement from a net loss of $19.9 million in the first quarter of 2025.
• As of March 31, 2026, the company had $219.5 million in cash, cash equivalents, and investments, which management believes is sufficient for at least twelve months of operations.
• The company repurchased approximately 1.46 million shares of Class A common stock for $2.6 million during the quarter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant revenue decline and continued substantial net losses, despite cost-saving measures and a strong cash position.

Positives

• Net loss improved by 16% to $16.8 million for the quarter compared to $19.9 million in the prior year.
• Operating expenses were reduced by 20% to $18.2 million, indicating cost management efforts.
• The company maintains a strong liquidity position with $219.5 million in cash, cash equivalents, and investments as of March 31, 2026, providing at least twelve months of operational runway.
• The company continues its share repurchase program, buying back approximately 1.46 million shares for $2.6 million in the quarter.

Negatives

• Total revenue decreased significantly by 34% to $2.8 million in Q1 2026 compared to $4.2 million in Q1 2025.
• Product revenue declined by 27% and service revenue by 55%.
• Gross profit decreased by 52% to $0.98 million.
• The company continues to incur substantial net losses, with a loss of $16.8 million in the quarter, and has an accumulated deficit of $482.8 million.
• Revenue is concentrated, with one customer accounting for 13% of total revenue in Q1 2026.

Risks

• The company has a history of net losses and negative cash flows, which are expected to continue, and there is no assurance of achieving future profitability.
• The size of the markets for the Proteograph Product Suite may be smaller than estimated, or new market opportunities may not develop as quickly as expected.
• Commercialization success depends on broad scientific and market acceptance of the Proteograph Product Suite, which may not be achieved.
• The company relies on a single contract manufacturer, Hamilton Company, for its instruments, posing a risk if this supplier fails or underperforms.
• Dependence on key personnel and the ability to attract and retain qualified employees is critical.
• The company faces significant competition from established life sciences technology companies.
• Future capital requirements may necessitate raising additional capital, which could dilute existing stockholders or impose restrictive debt covenants.
• The company's intellectual property portfolio is subject to various risks, including challenges to validity and enforceability, and potential infringement claims.
• The company is subject to various regulatory risks, particularly if its products are deemed medical devices or clinical diagnostics.
• Health epidemics and unfavorable economic conditions could adversely impact the business.
• Disruptions to information technology systems or data security breaches could harm the business.
• The company's Tax Benefit Preservation Plan could discourage a change in control.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the near term while investing in growth. Management believes current cash and investments are sufficient for at least twelve months of operations. Future capital requirements will depend on revenue growth, commercialization efforts, R&D, acquisitions, and other investments.

Management Comments

• Management believes that broader access to the proteome is essential for understanding biology and disease, and that the Proteograph can enable population-scale, deep, unbiased proteomics studies.
• The launch of the Proteograph ONE assay and SP200 automation instrument in May 2025 represents a transformative milestone, significantly improving the performance and scalability of deep, unbiased proteomic analysis.
• The commercial strategy is focused on growing adoption of the Proteograph, expanding the installed base, increasing utilization of consumables, and growing the service offering.
• Management believes that current cash and investments provide sufficient capital resources to continue operations for at least twelve months from the issuance date of the financial statements.

Industry Context

StockSavvy.ai notes that Seer, Inc.'s Q1 2026 results reflect the challenging commercialization phase for novel life sciences technologies. The reported revenue decline, while concerning, is common for companies in this stage, especially when facing market adoption hurdles for complex platforms like the Proteograph. The company's focus on improving scalability and addressing cost barriers in proteomics aligns with broader industry trends seeking more accessible and comprehensive biological insights.

Comparison to Industry Standards

• The proteomics market is still developing compared to the more mature genomics market. While Seer aims to enable large-scale studies, the adoption rate and cost-effectiveness compared to existing methods (e.g., mass spectrometry-based proteomics, antibody-based assays) are key benchmarks.
• Competitors like Thermo Fisher Scientific, Agilent Technologies, and Bruker offer a range of proteomics solutions. Seer's performance will be measured against their market penetration, technological advancements, and pricing strategies.
• The company's reported net loss of $16.8 million in Q1 2026 is substantial, but typical for pre-profitability life sciences companies investing heavily in R&D and commercialization. Benchmarking against peers in terms of R&D spend as a percentage of revenue and burn rate is crucial.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The company recognized $56,000 in revenue from PrognomiQ, Inc. for services in Q1 2026.
• The company made additional investments in PrognomiQ's Series D Preferred Stock, totaling $1.5 million in January 2026, bringing the total investment to $11.9 million. As of March 31, 2026, the carrying value of this investment was $3.1 million.

Stakeholder Impact

• Shareholders: The significant revenue decline and continued net losses may negatively impact the stock price. The share repurchase program could provide some support.
• Employees: Reductions in force and cost-saving measures may impact morale and workload. The company's ability to attract and retain talent remains critical.
• Customers: The company's focus on improving the Proteograph Product Suite and addressing cost barriers is intended to benefit researchers. However, revenue concentration poses a risk if key customers reduce orders.
• Suppliers: The company relies on third-party suppliers for components and a contract manufacturer for instruments, indicating ongoing relationships and potential supply chain considerations.

Next Steps

• Continue to broadly market and sell the Proteograph Product Suite.
• Attract, hire, and retain qualified personnel.
• Build out and expand in-house NP manufacturing capabilities.
• Continue research and development of other products and enhancements to the Proteograph Product Suite.
• Implement operational, financial, and management information systems.
• Obtain, maintain, expand, and protect the intellectual property portfolio.
• Build the infrastructure to operate and scale as a public company.

Key Dates

Recommendation

While the revenue decline and continued losses are concerning, the company's strong cash position, ongoing cost management, and potential for future market adoption of its technology warrant a hold. Investors should monitor revenue trends, customer adoption rates, and progress in R&D and commercialization efforts.

Keywords

Seer, Inc., 10-Q, Quarterly Report, Proteograph Product Suite, Proteomics, Life Sciences, Financial Results, Revenue, Net Loss, Stock Repurchase